- The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Thursday, January 17, to review and discuss Sanofi's (NASDAQ:SNY) marketing application seeking approval for orally administered Zynquista (sotagliflozin) as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes.
- Shares are up 1% premarket while co-development partner Lexicon Pharmaceuticals (NASDAQ:LXRX) is up 2%.
- FDA briefing doc
- Errata to FDA briefing doc
- Sanofi briefing doc